Pimecrolimus (Elidel


) and tacrolimus (Protopic  ) are calcineurin inhibitors used for the topical treatment of atopic dermatitis (Stuetz et al., 2006) . The compounds bind to cytoplasmic proteins of the immunophilin family, in particular to macrophilin12 (Kissinger et al., 1995) (Grassberger et al., 1999) which is highly and ubiquitously expressed (Galat, 2003) ; inhibition of calcineurin occurs in a ternary calcineurinimmunophilin-drug complex. Despite a high degree of structural similarity (Figure 1 ), pimecrolimus and tacrolimus display characteristic differences in terms of pharmacological profile (Stuetz et al., 2001; Meingassner et al., 2003; Grassberger et al., 2004; Bavandi et al., 2006; Kalthoff et al., 2007) , and physicochemical and pharmacokinetic properties. Regarding physicochemical properties, the higher lipophilicity of pimecrolimus is noteworthy: pimecrolimus features an 8-fold higher octanol-water distribution coefficient than tacrolimus (Billich et al., 2004) . Another distinguishing feature between the two agents is their rate of skin permeation: the permeation rate from 1% solutions is approximately 10-fold lower for pimecrolimus compared to tacrolimus (Billich et al., 2004) ; also from the marketed 1% cream the permeation rate of pimecrolimus is about 6-and 4.3-fold lower than from 0.1% and 0.03% tacrolimus ointments, respectively, despite the much higher pimecrolimus concentration in the formulation (Meingassner et al., 2005) . The reason for the pronounced difference in skin permeation of the two drugs has so far not been investigated in detail.
Low skin permeation is a favorable property for a topical drug, since it contributes to low systemic exposure levels and thus to a lower risk of systemic side effects. Indeed, topical pimecrolimus is associated with lower systemic drug exposure than tacrolimus (Draelos et al., 2005) . A comparison of systemic exposure levels should consider exposure to both total as well as unbound drug. The latter is relevant, since free rather than total drug concentrations may drive wanted or unwanted pharmacological effects. For tacrolimus very different unbound fractions in plasma of 1.2% and 27% have been reported based on different separation techniques (Piekoszewski et al., 1993; Zahir et al., 2001; Nagase et al., 1994) ; data on pimecrolimus have not been published so far.
Here we report on studies performed to better understand the cause of the difference in skin permeation between pimecrolimus and tacrolimus. In addition, we present data on comparative plasma protein binding, to allow for a comparison of systemic exposure to unbound drug and we identified the major binding partners in plasma for both drugs.
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Methods and Materials
Permeation assay. Permeation was studied using static Franz-type diffusion cells where silicone elastomer membranes (Dow-Corning, Coventry, UK; #7-4107; 75 µm thick) were mounted. The exposed membrane area was 2.54 cm 2 , and the volume of the receptor chamber was 5.8 mL. Phosphate buffered saline/ethanol 3:1 was used as receptor phase.
All experiments were performed at 32°C in triplicates for 48 hrs. Pimecrolimus and tacrolimus were applied to the membranes either in solution (propylene glycol/oleyl alcohol 9:1) at a concentration of 1 % (w/v) in a volume of 300 µL, or in their marketed formulations (Elidel, 1% pimecrolimus cream, Novartis; Protopic, 0.1 or 0.03% tacrolimus ointment, Astellas; applied amount: 300 mg).
Samples of 100 µL were withdrawn from the receptor phase at 4 to 8 time points during the 48-hr experiment and replaced by fresh receptor fluid. After addition of an internal standard, and dilution with 0.1 % formic acid/acetonitrile 50:50, these samples were analyzed directly by HPLC MS/MS (see below). The quantification of the parent ions was based on the area ratio of the fragment ions to the fragment ion of an internal standard. For calibration, receptor medium was spiked with variable amounts of the analytes resulting in concentrations of 1 to 1000 ng/ml.
Sample analysis. LC-MS/MS
Calibration curves were set up both with fresh medium and with medium taken at 48 hrs from permeation assays with formulations only (i.e. without active compound), to control for possible interference by excipients, which, however, was not observed. The limits of quantification for pimecrolimus and tacrolimus were 10 ng/mL in receptor fluid.
Calculation of flux was done as described (Schmook et al. 2001) .
Radiolabels and stock solutions. Tritium-labeled pimecrolimus (543.3 MBq/mg ) and tacrolimus (1035 MBq/mg; position of radiolabels are given in Figure 1 ) were prepared and supplied by the Isotope Laboratory of Novartis Pharma AG (Basel, Switzerland).
Ethanolic stock solutions were prepared by serial dilution including unlabeled compound resulting in final specific activities of 10.9-543 MBq/mg and 20.7 -207 MBq/mg for pimecrolimus and tacrolimus, respectively, and concentrations of 2 -100 µg/mL (1000-times final assay concentrations).
Biological matrices. Human plasma (lithium heparin as anticoagulant, plasma pools from three healthy male donors) was delivered frozen from EFS-ALSACE, Strasbourg, France. Fibrin in plasma was removed by centrifugation for 10 min at 10000 g at room temperature and cleared plasma was frozen in aliquots at -20°C and defrosted before use. analyzed by equilibrium gel filtration (Hummel et al., 1962) (Berger et al., 2003) . Two were determined by LSC using the respective specific activities.
Data analysis. In contrast to the Superose 6 10/300 column the HiTrap Desalting column does not separate proteins (> 5 kDa) but the total protein runs faster than free a physiologically relevant concentration of the particular plasma protein (Table 3) . 
Results
Permeation through a silicone membrane. We compared permeation of pimecrolimus and tacrolimus through a silicon elastomer membrane; such membranes are commonly used as artificial barriers for drug release studies from topical formulations. For both agents the permeation rate through the silicon membrane was nearly identical (Table 1) when applied as 1% solutions in propylene glycol/oleyl alcohol 9:1. Permeation was also tested for the marketed formulations of the two drugs. When applying Elidel (1% pimecrolimus cream), to the artificial membrane, permeation of pimecrolimus was 5.7-fold lower than from the 1% pimecrolimus solution, indicating somewhat lower release from the cream. Using Protopic (0.1% and 0.03% tacrolimus ointment) lower permeation as compared to Elidel was observed with the membrane. The differences in flux roughly reflected the differences in drug concentrations (Table 1 ). This suggests that the difference in drug concentration causes the difference in flux and confirms very similar permeation characteristics for pimecrolimus and tacrolimus through the artificial membrane. In contrast, as reported previously (Billich et al., 2004 , Meingassner et al., 2005 , the skin permeation of the two agents differs markedly, whether applied as 1% solutions or as commercial crème and ointments, respectively, and being 4-10 times lower for pimecrolimus compared to tacrolimus (Table 1) .
Binding to soluble skin proteins. To shed light on the observed differences in skin permeation of pimecrolimus and tacrolimus, binding to a preparation of soluble skin proteins was analyzed. For both drugs the amount bound per milligram of protein increased apparently linearly with the free drug concentration, in the concentration range covered, however, particularly at high concentrations the experimental scatter was This article has not been copyedited and formatted. The final version may differ from this version. (Figure 2A ), suggesting a generally higher affinity of pimecrolimus in binding to soluble skin proteins.
To identify any major binding proteins in the skin preparation, the proteins were separated on a Superose 6 column equilibrated with pimecrolimus or tacrolimus. For both drugs only one major specific peak was identified. It eluted at a molecular weight of approximately 15 kDa ( Figure 2B ). The amount of compound in this peak was similar for both compounds: 13.5 ± 2.4 ng and 12.7 ± 3.5 ng per mg protein (total protein injected), for pimecrolimus and tacrolimus, respectively (n = 3). These values correspond roughly to the y-axis intercept, when total binding is plotted over the free drug levels ( Figure 2A ).
This could result from saturation of the 15-kDa binding protein at all tested drug concentrations, due to a dissociation constant below the lowest tested concentration.
Plasma protein binding. Using equilibrium gel filtration on HiTrap Desalting columns
we observed that at similar free concentrations of pimecrolimus and tacrolimus about 9-fold less of the latter was bound to plasma proteins ( Figure 3A ). Based on binding data at free concentrations of 0.48 to 93.3 ng/mL (pimecrolimus) and 3.3 to 80.2 ng/mL (tacrolimus), unbound fractions of pimecrolimus and tacrolimus in human plasma were estimated to be 0.4 ± 0.1% and 3.7 ± 0.8%, respectively ( tacrolimus, the binding to purified human plasma proteins was analyzed (Table 3) . At physiologically relevant concentrations of the different proteins, binding of pimecrolimus was estimated to be highest to lipoproteins, particularly to HDL. For tacrolimus, binding was highest to HDL, followed by VLDL and α 1 -acid glycoprotein. Binding to α 1 -acid glycoprotein and γ-globulins was similar for pimecrolimus and tacrolimus. In contrast, binding to human serum albumin and lipoproteins was 5 -9 fold higher for pimecrolimus (Figure 4) , which likely causes the overall higher binding of pimecrolimus in plasma.
To substantiate these results, binding to human plasma was analyzed on a Superose 6 gel filtration column. When plasma proteins were separated on a column equilibrated with pimecrolimus, the bulk of pimecrolimus eluted at the expected elution volumes of HDL (≥ 170 kDa, major peak) and LDL (approximately 3500 kDa) ( Figure 3B ). The very broad peaks were in line with the variable molecular weight of lipoproteins, which are composed of apoproteins and lipids in somewhat varying ratios. The major protein peak at approximately 70 kDa ( Figure 3B , UV trace), which corresponds mainly to albumin, was not linked to a pimecrolimus peak, confirming that albumin was less relevant for the overall plasma protein binding of pimecrolimus. In contrast to what could be expected from the experiment using purified plasma proteins (Table 3) , no peak was found at the expected molecular weight of VLDL. This is likely due to removal of floating VLDL during plasma preparation for injection (removal of fibrin, see Methods).
Upon separation of human plasma proteins on a Superose 6 column equilibrated with tacrolimus, the highest and relatively slim tacrolimus peak concurred with the second half of the main protein peak ( Figure 3B ). This corresponds likely to α 1 -acid glycoprotein bound tacrolimus. α 1 -Acid glycoprotein is expected to elute slightly later than serum This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
We recently reported that the rate of permeation through human skin is lower for pimecrolimus than for tacrolimus, when comparing 1% solutions as well as the marketed formulations of the two drugs (Table 1, Billich et al., 2004; Meingassner et al., 2005) . This is in line with lower systemic exposure observed in patients treated with pimecrolimus cream as compared to those treated with tacrolimus ointment in atopic dermatitis (Draelos et al., 2005) and Netherton syndrom (Oji et al., 2005; Allen et al., 2001) . In the present studies we found that permeation through an artificial membrane was similar for the two drugs (Table 1 ). The latter result indicates that the lower permeation of pimecrolimus through skin into the receptor fluid is not caused by a significantly slower release of the compound from the formulations as compared to tacrolimus, nor by a limited solubility of pimecrolimus in the receptor fluid. Rather it appears that the distribution equilibrium between skin and receptor fluid is more on the side of the skin in the case of pimecrolimus, leading to a markedly reduced permeation through skin compared to tacrolimus. These observations point to a stronger binding of pimecrolimus to components of the skin, compared to tacrolimus.
To test this hypothesis, we investigated binding of pimecrolimus and tacrolimus to a preparation of soluble skin proteins. It is important to note, that many major components of the skin, like e.g. collagen fibers or horny skin, are not covered by these experiments.
In the skin protein preparation we identified one specific binding protein with a molecular macrophilins) which comprises members with molecular weights close to 15 kDa, of which the FKBP12 or macrophilin12 is the best characterized and most prevalent (Galat, 2003) . At very low free concentrations this low capacity and high affinity binding might result in similar amounts bound for pimecrolimus and tacrolimus. However, at higher free drug concentrations the protein preparation had approximately 3-fold more pimecrolimus bound as compared to tacrolimus, suggesting a higher affinity of pimecrolimus in this less specific binding. This result may explain the slower skin permeation of pimecrolimus: Due to the high local drug concentration following topical administration, the unspecific high-capacity binding is likely dominating binding in the upper skin layers.
In deeper layers at low total concentrations the specific binding would be similar, Grassberger et al., 1999) . This suggests that at low total concentrations the free tacrolimus concentration would be lower and therefore the pull from deeper layers even somewhat higher for tacrolimus.
In plasma we found that lipoproteins contributed strongly to the overall binding of pimecrolimus and tacrolimus, in line with published data for tacrolimus (Nagase et al., 1994) . Using ultracentrifugation, an unbound fraction for both drugs of 20 to 30% in human plasma was determined ( (Piekoszewski et al., 1993) internal data). However, while most of the total plasma protein can be separated by ultracentrifugation, lipoproteins can -depending on their characteristic density -either float or sediment very slowly or not at all (Olson, 1998) , preventing a complete separation by ultracentrifugation. Therefore, plasma protein binding results based on ultracentrifugation are misleading in case of highly lipoprotein bound drugs, since they will underestimate the extent of protein binding. For tacrolimus a 20-fold lower unbound plasma fraction of 1.2% was measured employing ultrafiltration and equilibrium dialysis (Zahir et al., 2001; Nagase et al., 1994) . This is closer to but approximately 3-times lower than the 3.7% determined in the present study by equilibrium gel filtration. These studies employing ultrafiltration and equilibrium dialysis may underestimate the concentration of tacrolimus in plasma water e.g. due to wall binding or binding to the membrane used for separation as suggested previously (Venkataramanan et al., 1995) . Also with equilibrium gel filtration we experienced significant drug adsorption to the column. However, the actual free concentration could be determined accurately, due to use of radiolabeled drugs, large volumes available for measurement and lack of pipetting steps. Gel filtration separates molecules according to size by providing different bed volumes for differently sized molecules. When the system is equilibrated with the drug, the larger and faster moving proteins are always exposed to the same free drug concentration leading to equilibration (Hummel et al., 1962; Berger et al., 2003) . Here, in addition to a protein separating gel filtration column, we used desalting columns, which only separate small molecules (≤ 1 kDa) from large molecules (≥ 5 kDa, group separation). This allows for short running times and an accurate determination of total binding in a complex mixture of proteins like e.g. plasma. The method is very powerful to determine differences in The unbound fraction of pimecrolimus in human plasma was determined here to 0.4%, i.e. about 9-fold lower than for tacrolimus. Reported clinical exposure levels for both drugs are based on blood concentrations (Draelos et al., 2005) . Exposure to free drug can be derived using blood distribution data. In the relevant concentration range the fraction in plasma is 12% for pimecrolimus versus 2-5% for tacrolimus (Nagase et al., 1994 , Zollinger et al., 2006 . This partly compensates the observed difference in protein binding; therefore at similar total blood concentrations the free concentration would be 2 -4 fold lower for pimecrolimus.
For pimecrolimus, binding to plasma lipoproteins was higher compared to binding to albumin and α 1 -acid glycoprotein, the two main drug binding plasma proteins (Table 3) .
Binding of both drugs was highest to HDL, consistent with reported data for tacrolimus (Zahir et al., 2001; Nagase et al., 1994) . α 1 -Acid glycoprotein contributed substantially to the binding of tracrolimus in plasma (Table 3) , which agrees with the finding that the unbound fraction of tacrolimus correlates with α 1 -acid glycoprotein as well as HDLcholesterol levels (Zahir et al., 2004) (Olson, 1998; Ginsberg, 1998) . Pimecrolimus is mainly cleared by hepatic oxidative metabolism, followed by biliary excretion of metabolites (Zollinger et al., 2006) and also tacrolimus is mainly cleared by liver metabolism (Venkataramanan et al., 1995) . While lipoprotein binding limits the free drug concentration and with it its liver and overall organ uptake e.g. by passive diffusion, high lipoprotein binding may on the other hand enhance drug uptake via lipoprotein-coupled transport into the liver. To clarify how strongly lipoprotein mediated uptake contributes to the overall liver uptake of pimecrolimus and tacrolimus would need further investigations. However, the effect might be more pronounced for the higher lipoprotein bound pimecrolimus, potentially contributing to a higher systemic clearance. A direct comparison of the systemic blood clearance of the two drugs is not possible, since for pimecrolimus no intravenous pharmacokinetic study was performed. The blood clearance of tacrolimus is 4 -6 L/h, (Venkataramanan et al., 1995) which is likely lower than the blood clearance of pimecrolimus (CL/f: 72 L/h, (Zollinger et al., 2006) ).
In conclusion, the current study highlights the importance of binding interactions and the interplay between specific high affinity and unspecific high capacity binding of topically applied drugs, for controlling drug exposure at the target site and in the systemic circulation. The presented in vitro data suggest that higher unspecific binding to skin 
H-labeled pimecrolimus (A) and tacrolimus (B).
The * denotes the position of 3H-label the UV signal is in arbitrary units.
Fig. 4. Relative binding of pimecrolimus and tacrolimus to human plasma proteins
Binding of pimecrolimus to human plasma proteins relative to tacrolimus binding was calculated as ratio of the mean unbound fractions given in Table 3 .
This article has not been copyedited and formatted. The final version may differ from this version. Table 2 . Binding of pimecrolimus and tacrolimus to human plasma proteins 100 µL of plasma per run were loaded onto a gel filtration column equilibrated with either pimecrolimus or tacrolimus at different concentrations (n = 3 for each concentration). Table 3 . Binding of pimecrolimus and tacrolimus to isolated human plasma proteins
Mean
